Interim Chief Financial Officer · GYRE THERAPEUTICS, INC. (GYRE)

Seline Miller

FY2021 is the first fiscal year CompBrief holds for Seline Miller as a named executive officer of GYRE THERAPEUTICS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$313,339

Salary $201,426Stock awards $0Bonus $53,455

5th of 5 named executive officers at Gyre Therapeutics by FY2021 total.

5 named officers on file for GYRE THERAPEUTICS, FY2021

Seline Miller’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how GYRE THERAPEUTICS’s whole pay program stands against its peers

  • GYRE THERAPEUTICS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on GYRE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed July 19, 2022 (DEF 14A).

Free

Get Seline Miller’s full pay file as a PDF — free

More than this page: up to 10 years of Seline’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Seline Miller compensation by year

GYRE THERAPEUTICS Summary Compensation Table · the one fiscal year held
In US dollars, as GYRE THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$201,426
Bonus$53,455
Stock awards$0
Option awards$58,458
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$313,339

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GYRE THERAPEUTICS, INC. DEF 14A filed July 19, 2022, accession 0001140361-22-026309, and prior-year filings. Open the filing on EDGAR.

How this page was built: the GYRE THERAPEUTICS, INC. filed document, accession 0001140361-22-026309. Every figure is read from that document and cited to the page and table it appears in. Filed July 19, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option16,000—$4.81

Per the Outstanding Equity Awards at Fiscal Year-End table in GYRE THERAPEUTICS, INC.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

GYRE THERAPEUTICS’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Nassim UsmanPresident and Chief Executive Officer$1,235,751
Grant BlouseChief Scientific Officer$736,694
Clinton MusilFormer Chief Financial Officer$649,624
M.B.B.Ch. Howard LevyFormer Chief Medical Officer$618,254
Seline Miller · this pageInterim Chief Financial Officer$313,339

The full GYRE THERAPEUTICS compensation record

free company brief

This page is one person within GYRE THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GYRE THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Seline Miller's compensation dossier · One-time report. No refunds.